Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $267.7 million.

  • Neurocrine Biosciences' Change in Acquisitions & Divestments rose 673.84% to $267.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 1259.95%. This contributed to the annual value of $1.1 billion for FY2025, which is 1259.95% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $267.7 million, which was up 673.84% from $225.0 million recorded in Q3 2025.
  • Neurocrine Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $298.6 million during Q2 2025, with a 5-year trough of $161.3 million in Q1 2021.
  • Its 4-year average for Change in Acquisitions & Divestments is $245.4 million, with a median of $265.3 million in 2024.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 2188.86% in 2021, then soared by 7053.11% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Change in Acquisitions & Divestments (Quarter) stood at $161.3 million in 2021, then skyrocketed by 80.29% to $290.8 million in 2023, then decreased by 13.76% to $250.8 million in 2024, then grew by 6.74% to $267.7 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $267.7 million for Q4 2025, versus $225.0 million for Q3 2025 and $298.6 million for Q2 2025.